9/26/2013

China's Food and Drug Administration approved Zhejiang Huahai Pharma's application to manufacture efavirenz, an oral non-nucleoside reverse transcriptase inhibitor, to control the symptoms of AIDS.

Full Story:
BioSpectrum Asia

Related Summaries